20/20 Biolabs, INC

8-K

Market Movers (8-K)

NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 BioLabs Reports Record Cancer Test Revenue, Boosts Cash
20/20 BioLabs announced record quarterly revenue for its multi-cancer early detection test, a 47% year-over-year increase, alongside a strengthened cash position and elimination of convertible note debt.
Capital raise
Better than expected
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Eyes Medicare Reimbursement for Cancer Test
20/20 Biolabs presented an investor webinar on August 5, 2026, detailing progress on its OneTest for Cancer and Longevity, emphasizing the potential impact of new Medicare reimbursement pathways for multi-cancer early detection tests.
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Enters Standstill with Investor, Faces Nasdaq Bid Price Concern
20/20 Biolabs, Inc. has entered into a 120-day standstill agreement with Streeterville Capital, LLC, while also receiving a notice from Nasdaq regarding non-compliance with the minimum bid price rule.
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Investor Webinar: Medicare Reimbursement Pathway
20/20 Biolabs presented its OneTest multi-cancer early detection (MCED) test, highlighting a potential Medicare reimbursement pathway established by recent legislation and contrasting its approach with ctDNA-based tests.